MARKET

IONS

IONS

Ionis Pharmaceuticals
NASDAQ
38.20
+0.17
+0.45%
Closed 19:37 12/07 EST
OPEN
38.00
PREV CLOSE
38.03
HIGH
38.80
LOW
37.75
VOLUME
1.15M
TURNOVER
--
52 WEEK HIGH
48.82
52 WEEK LOW
28.25
MARKET CAP
5.43B
P/E (TTM)
659.76
1D
5D
1M
3M
1Y
5Y
Biogen's (BIIB) ALS Drug Tofersen Filing Accepted in Europe
Biogen's (BIIB) tofersen, if approved, will be the first genetically-targeted treatment for SOD1-ALS in Europe.
Zacks · 1d ago
BRIEF-Ionis Says EMA Accepts Marketing Authorization Application Of Tofersen
Reuters · 2d ago
Ionis in partnership with Metagenomi on developing medicines for genetic targets
Seekingalpha · 11/14 17:14
BRIEF-Ionis Partners With Metagenomi To Add Gene Editing To Its Broad Technology Platform
Reuters · 11/14 11:08
Ionis Pharmaceuticals, Metagenomi Sign Collaboration Deal To Produce Investigational Medicines
Ionis Pharmaceuticals, Metagenomi Sign Collaboration Deal To Produce Investigational Medicines
MT Newswires · 11/14 06:50
BRIEF-Ionis Presents Positive Phase 2 Data From Open Label Extension Study Of Donidalorsen At 2022 ACCAI Annual Meeting
Reuters · 11/13 18:21
Should You Be Worried About Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) 1.2% Return On Equity?
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
Simply Wall St. · 11/11 13:23
Research Alert: CFRA Keeps Sell Opinion On Shares Of Ionis Pharmaceuticals
Research Alert: CFRA Keeps Sell Opinion On Shares Of Ionis Pharmaceuticals
MT Newswires · 11/10 17:28
More
About IONS
Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company is primarily focused on our cardiovascular and neurology franchises. Its products include SPINRAZA, TEGSEDI and WAYLIVRA. SPINRAZA is for the treatment of patients of all ages with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. TEGSEDI is for the treatment of patients with polyneuropathy caused by hereditary transthyretin (TTR), amyloidosis (hATTR), a debilitating, progressive, and fatal disease. WAYLIVRA is an antisense medicine indicated as an adjunct to diet in adult patients. The Company has over six medicines in Phase III studies for eight indications, which include Eplontersen (TTR), Olezarsen (ApoC-III), Donidalorsen (PKK), ION363 (FUS), Pelacarsen (Apo(a)) and Tofersen (SOD1). Its cardiovascular medicine in development includes Eplontersen, Olezarsen, Pelacarsen, ION449 (PCSK9), Fesomersen and IONIS-AGT-LRx.

Webull offers kinds of Ionis Pharmaceuticals Inc stock information, including NASDAQ:IONS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IONS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IONS stock methods without spending real money on the virtual paper trading platform.